MedTrace Logo

Coenzyme Q-10 and Pulmonary Arterial Hypertension

NCT01148836 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-03-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the effects of Coenzyme Q-10, an antioxidant, in the treatment of pulmonary hypertension.

Conditions

Interventions

DIETARY_SUPPLEMENT

Coenzyme Q-10 in Pulmonary Hypertension subjects

Take 100mg Co-Q for three times daily

DIETARY_SUPPLEMENT

Coenzyme Q-10 in Normal Control subjects

Take 100mg Co-Q for three times daily

Sponsors & Collaborators

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Jackie Sharp, CNP · The Cleveland Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2014-01-31
Completion
2014-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01148836 on ClinicalTrials.gov